Document is current
Any future updates will be listed below
-
Authors
Taylor, Peter C.
Kadakia, Aditi
Milligan, Jack
Romero, Ana
Howell, Oliver
Patel, Pankaj A.
Barlow, Sophie
Caporali, Roberto
- License Information
-
More Information
Article History
Received: 15 December 2025
Accepted: 31 March 2026
First Online: 14 April 2026
Declarations
:
: Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors. Peter C. Taylor: Research grants from: Alfasigma; consultancy fees from: AbbVie Inc., Eli Lilly, Fresenius, Alfasigma, Gilead, Janssen, Nordic, Takeda, and UCB; participation on a Data Safety Monitoring Board/Advisory Board for Immunovant, Sanofi, and MoonLake. Aditi Kadakia: Employee of AbbVie, Inc., and may hold stock or options. Ana Romero: Employee of AbbVie, Inc., and may hold stock or options. Pankaj A. Patel: Employee of AbbVie, Inc., and may hold stock or options. Jack Milligan: Employee of Adelphi Real World, who acted as a consultant to AbbVie Inc. for this analysis and has no other conflicts of interest. Oliver Howell: Employee of Adelphi Real World, who acted as a consultant to AbbVie Inc. for this analysis and has no other conflicts of interest. Sophie Barlow: Employee of Adelphi Real World, who acted as a consultant to AbbVie Inc. for this analysis and has no other conflicts of interest. Roberto Caporali: Received speaker and/or consultant fees from AbbVie Inc., Alfasigma, Accord, Celltrion, Eli Lilly, Fresenius, Galapagos, Janssen, MSD, Novartis, Pfizer, and UCB.
: Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association (EphMRA) guidelines [ ], and therefore it does not require ethics committee approval. The research was submitted to the Institutional Review Board (IRB), study protocol number: Protocol #21-ADRW-104. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [ ], Health Information Technology for Economic and Clinical Health Act legislation [ ], and the 1964 Declaration of Helsinki and its later amendments. The US, Japan, and Canada are signatories to the EphMRA Code of Conduct.
